NCT04106700 - Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

August 26, 2020

Study Completion Date

October 5, 2020

Conditions

Venous Thromboembolism

Interventions

DRUG

Apixaban 2.5 MG

Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient

Trial Locations (4)

46010

Hospital Clinico Universitario, Valencia

46017

Hospital Universitario Doctor Peset, Valencia

46026

Hospital Universitario y Politécnico La Fe, Valencia

Unknown

Hospital General Universitario, Valencia